WSJ Article - Merck Pursues Biotech Seagen
Amazing the
WSJ Article - Merck Pursues Biotech Seagen
Amazing the parallels between this company and us. Both based in WA state, both between CEOs, both have a cancer drug being tried in combination with existing therapy, and i think their drug is a MAB also.
Of course, the difference is that Seagen has an approval, and generates revenue. Incredibly, it has a market cap of $30 Billion on just $1.6 Billion in revenue. That's a 19X revenue multiple - shows how much money we all make if we could just start generating revenue.
Article also mentions that M&A hit an all time high last year, and down 50% this year - but still good. In other words, we're still in the golden window of being bought - but nothing lasts forever.
It's time for us to get out on the field. There's one helluva game taking place out there - and it's just waiting for us. Companies are dying to buy a quality drug like ours - and make us rich in the process. But we've got to make some progress, get this regulatory hold lifted, and finally leave the locker room and get out on the field.
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hong Kong Wine & Dine Festival Returns This October HONG KONG, an anticipated gastronomic spectacle is set for the latter part of October. The Hong Kong Wine & Dine Festival will take place from 23 to 26 October 2025 at the iconic Central Harbourfront. This annual celebration is designed to showcase the best in culinary arts and exquisite wines, offering something special...
Continue Reading
Danaher Sets Date for Q3 2024 Earnings Conference Call Danaher Corporation (NYSE: DHR) has announced the date for its highly anticipated quarterly earnings conference call. This event is significant for investors and stakeholders who keep a close eye on the company's developments. Earnings Call Details The earnings call is set for an upcoming Tuesday morning, during which...
Continue Reading
UniQure Stock Reaches New Heights UniQure NV (QURE) has exciting news as its stock recently touched an impressive 52-week high of $18.5. This remarkable milestone is a testament to the company's resilient growth strategy and innovative advancements in the biotechnology industry. With a market capitalization reaching $885 million, the stock has seen an astonishing rise of...
Continue Reading
MedCana Enters Negotiations for Cannabis Supply Agreement MedCana, a prominent player in the pharmaceutical-grade cannabis landscape, is making headlines with an exciting new development from its subsidiary in Colombia. The company is set to negotiate a substantial supply agreement worth between $1.2 million and $2.4 million annually. This agreement marks a significant...
Continue Reading
Mouawad Teams Up with OCTA Properties for Luxe Residences OCTA Properties has been selected as the global licensee for residences branded by Mouawad, bringing the brand's legacy of timeless elegance into the realm of premium real estate. This partnership marks an exciting new chapter in Mouawad's prestigious journey in luxury development. A Landmark Collaboration Mouawad,...
Continue Reading